stoxline Quote Chart Rank Option Currency Glossary
  
Verastem, Inc. (VSTM)
9.84  -0.39 (-3.81%)    04-19 16:00
Open: 10.1
High: 10.355
Volume: 150,979
  
Pre. Close: 10.23
Low: 9.56
Market Cap: 249(M)
Technical analysis
2024-04-19 5:13:08 PM
Short term     
Mid term     
Targets 6-month :  13.28 1-year :  14.59
Resists First :  11.37 Second :  12.5
Pivot price 11.26
Supports First :  9.56 Second :  7.95
MAs MA(5) :  10.58 MA(20) :  11.38
MA(100) :  10.53 MA(250) :  9.18
MACD MACD :  -0.4 Signal :  -0.2
%K %D K(14,3) :  5.6 D(3) :  5.9
RSI RSI(14): 33.1
52-week High :  15.11 Low :  4.32
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ VSTM ] has closed below the lower bollinger band by 10.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 0.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.42 - 10.52 10.52 - 10.58
Low: 9.36 - 9.48 9.48 - 9.56
Close: 9.7 - 9.9 9.9 - 10.03
Company Description

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Headline News

Wed, 17 Apr 2024
Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer - The Globe and Mail

Sat, 13 Apr 2024
Verastem, Inc. (NASDAQ:VSTM) Short Interest Update - MarketBeat

Fri, 12 Apr 2024
Verastem (NASDAQ:VSTM) Shares Cross Above Two Hundred Day Moving Average of $9.47 - MarketBeat

Thu, 04 Apr 2024
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Wed, 20 Mar 2024
Verastem CEO sells shares worth over $4,500 By Investing.com - Investing.com

Fri, 15 Mar 2024
Verastem Inc. at a Crossroads: Navigating the Perilous Terrain of Patent Ownership and IP Rights - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 25 (M)
Shares Float 14 (M)
Held by Insiders 0.5 (%)
Held by Institutions 66.7 (%)
Shares Short 634 (K)
Shares Short P.Month 763 (K)
Stock Financials
EPS -3.97
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.26
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -47.1 %
Return on Equity (ttm) -138.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.64
Qtrly Earnings Growth 0 %
Operating Cash Flow -86 (M)
Levered Free Cash Flow -51 (M)
Stock Valuations
PE Ratio -2.49
PEG Ratio -1.8
Price to Book value 4.33
Price to Sales 0
Price to Cash Flow -2.88
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android